Nektar TherapeuticsNKTRNASDAQ
Loading
Operating Income Growth Under PressureDecelerating
Percentile Rank29
Studio
Year-over-Year Change

Year-over-year operating income growth rate

Percentile
P29
Within normal range
vs 5Y Ago
-1.8x
Contraction
Streak
3 yr
Consecutive declineDecelerating
PeriodValue
2025-24.31%
202423.45%
202342.80%
202246.15%
2021-17.42%
202013.66%
2019-163.96%
20181253.44%
201747.15%
2016-284.24%